What did the FDA’s accelerated approval of dostarlimab for rectal cancer actually mean — and who is it for?

On October 19, 2026, the FDA granted accelerated approval to dostarlimab-gxly for adults with stage II or III MSI-H/dMMR locally advanced rectal cancer, confirmed by an FDA-authorised test. In the AZUR-1 trial, 47 percent of centrally reviewed patients had a clinical complete response sustained at 12 months. This is early evidence for a specific biomarker group — not a general cure.

A cancer approval headline deserves a careful read — this one is genuinely significant, and genuinely narrow. Short answer: on October 19, 2026, the FDA granted accelerated approval to dostarlimab-gxly for adults with stage II or III locally advanced rectal cancer whose tumours are MSI-H or dMMR — a specific biomarker pattern — confirmed by an FDA-authorised test. It is the first immunotherapy approved for this group.

Why the biomarker decides everything: MSI-H/dMMR tumours account for only about 5 to 10 percent of rectal cancers, so testing at diagnosis is essential — this approval does not apply to the other 90-plus percent. In the single-arm phase 2 AZUR-1 trial, 47 percent of 116 centrally reviewed patients achieved a clinical complete response sustained at 12 months, and 71 percent of 154 treated patients received dostarlimab alone, with no additional treatment. That matters because standard care — chemotherapy, radiation and surgery — can leave lasting bowel, urinary and sexual effects, so a nonoperative path is a serious quality-of-life question for the people in this group.Read the approval precisely:1.

Accelerated approval runs on early evidence. It is granted so promising treatments reach patients sooner, and confirmatory studies are still required to prove the benefit holds.2. The trial was single-arm.

There was no comparison group, so the numbers are encouraging evidence — not a final verdict.3. Eligibility starts with a test. If you or a family member faces this diagnosis, ask whether the tumour has been tested for MSI-H/dMMR status.4.

This is not a general cure. It is early evidence for one specific biomarker group. Anyone weighing it should talk it through with their oncologist, who knows the full picture.Pro tip: When a headline says “complete response,” check two things — how many patients, and sustained for how long.

Here both numbers are stated plainly, which is exactly how early evidence should be reported and read.Ad’s take: For the small group this applies to, avoiding surgery can change a life — and the honest limits matter just as much as the hope. Tested, specific, still being confirmed: that is the accurate summary.